Engagements

Shire acquisition of Dyax

Charles River Associates medicine on money

In the US, a team of CRA consultants advised counsel to Shire on its acquisition of Dyax, a small pharmaceutical company with pipeline products to treat hereditary angioedema (HAE). The deal, reviewed by the FTC, closed with no divestitures.

Related capabilities

Life Sciences
Mergers & Acquisitions

Andrew R. Dick
Vice President

Washington, DC
+1-202-662-3898 adick@crai.com
Peter Boberg
Vice President

Boston
+1-617-425-3175 pboberg@crai.com

Antitrust & Competition
CRA Insights

Does your merger trigger Canada’s “rebuttable structural presumption”?

This article, authored by CRA’s Ian Cass, provides a brief reference guide along with a visual tool to help assess whether a merger meets the prescribed market...
Antitrust & Competition
Books

Antitrust Economics for Lawyers 2026

Designed for antitrust practitioners without requiring an economics background, the book explains complex concepts in an accessible but rigorous way, pairing...

Explore our thinking

Shire acquisition of Dyax

Key contacts

Related insights

Does your merger trigger Canada’s “rebuttable structural presumption”?

Antitrust Economics for Lawyers 2026